Site search

Clear filter
2855 results for '' found
TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer [NSCLC] receiving eftilagimod alfa [MHC class II agonist] in combination with
TACTI-004, a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer [NSCLC] receiving eftilagimod alfa [MHC class II agonist] in combination with
/
Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death
Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death
/
A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone [BRd] versus daratumumab, lenalidomide, and dexamethasone [DRd] in
A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone [BRd] versus daratumumab, lenalidomide, and dexamethasone [DRd] in
/
An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept [MK-7962] Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension [PAH] o
An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept [MK-7962] Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension [PAH] o
/
Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adu
Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adu
/
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate [ANZUP1801]. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutam
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate [ANZUP1801]. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutam
/
Phase III, multicentre, randomised,  double-blinded, placebo-controlled,  MAMS trial of SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression (STO
Phase III, multicentre, randomised, double-blinded, placebo-controlled, MAMS trial of SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression (STO
/
A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants of previous amlitelimab clinical trials in moderate to severe a
/
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and N
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and N
/
A Clinical Evaluation of the Efemoral Vascular Scaffold System [EVSS] for the Treatment of Patients with Symptomatic Peripheral Vascular Disease from Stenosis or Occlusion of the Femoropopliteal
A Clinical Evaluation of the Efemoral Vascular Scaffold System [EVSS] for the Treatment of Patients with Symptomatic Peripheral Vascular Disease from Stenosis or Occlusion of the Femoropopliteal
/
7 8 9 10 11